|
Ear assessments and nasopharyngeal carriage at the end of therapy |
|||
| Amoxicillin |
Placebo |
||
| n = 52 |
n = 51 |
||
|
|
|||
| Mean duration of therapy (months) |
5.7 |
5.2 |
|
| Mean age (months) at the end of therapy |
11.5 |
10.2 |
|
| Number of children (%) with the following worst ear status at the end of therapy |
|||
| Amoxicillin |
Placebo |
Risk Difference |
|
| n = 52 |
n = 51 |
[95% CI] |
|
| Success (bilateral normal ears at 2 successive monthly visits) |
5 (9.6%) |
0 |
+9.6% [1.6, 17.6] |
| Normal |
6 (12%) |
0 |
+12% [3, 20] |
| OME |
28 (54%) |
26 (51%) |
+3% [-16, 22] |
| AOM without perforation |
12 (23%) |
11 (22%) |
+1.5% [-15, 18] |
| AOM with perforation |
5 (10%) |
11 (22%) |
-12% [-26, 2] |
| Dry perforation |
0 |
1 (2%) |
-2% [-6, 2] |
| CSOM |
1 (2%) |
2 (4%) |
-2% [-9, 5] |
| Any suppurative OM† |
18 (35%) |
24 (47%) |
-12% [-31, 6] |
| Any perforation‡ |
6 (12%) |
14 (27%) |
-16% [-31, -1] |
| Any active perforation§ |
6 (12%) |
13 (26%) |
-14% [-29, 1] |
| Bilateral AOM without perforation |
4 (8%) |
7 (13%) |
+5% [-6, 17] |
| Bilateral any perforation‡ |
1 (2%) |
7 (14%) |
-12% [-22, -2] |
| Number of children (%) with nasopharyngeal carriage of the following OM pathogens¥ at end of therapy |
|||
| Amoxicillin |
Placebo |
Risk Difference |
|
| n = 50 |
n = 47 |
[95% CI] |
|
| Streptococcus pneumoniae |
29 (58%) |
33 (70%) |
-12% [-31, 7] |
| non-capsular Haemophilus influenzae |
36 (72%) |
29 (62%) |
+10% [-8, 29] |
| Moraxella catarrhalis |
44 (88%) |
43 (91%) |
-3% [-16,9] |
| All Spn, NCHi and M.cat |
23 (46%) |
21 (45%) |
1% [-19, 21] |
| Penicillin non-susceptible Spn‡ |
17 (34%) |
19 (40%) |
-6% [-26, 13] |
| Penicillin resistant Spn†† |
1 (2%) |
2 (4%) |
-2.3% [-9, 5] |
| NCHi beta-lactamase positive |
6 (12%) |
1 (2%) |
+10% [-0.03, 20] |
|
≸AOM, AOMwiP or CSOM; ‡ AOMwiP, dry perforation or CSOM; §AOMwiP or CSOM; ¥ Spn Streptococcus pneumoniae. NCHi non-capsular Haemophilus influenzae. Mcat Moraxella catarrhalis. ‡Penicillin intermediate or resistant Spn (MIC > = 0.1 μg/ml) ††Penicillin resistant Spn (MIC > 1.0 μg/ml) | |||
Leach et al. BMC Pediatrics 2008 8:23 doi:10.1186/1471-2431-8-23 |
|||